Laboratorios Farmaceuticos Rovi SA 2014 AR2
The report highlights Laboratorios Farmacéuticos ROVI's financial and non-financial performance for the fiscal year 2014, marking its first integrated report. The company achieved record results with a net profit of 24.1 million euros and total revenues of 240.9 million euros, representing a 10% increase from the previous year. ROVI expanded its workforce by 13% to 1,109 employees and invested 12.0 million euros in research and development, particularly focusing on its Risperidone ISM project. Environmentally, the company reduced its water consumption by 8% and electricity consumption by 1% at the group level, while investing 1.9 million euros in health and safety preventive actions.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2014
Type: AR2
Pages: 100
Back to company
Laboratorios Farmaceuticos Rovi SA
Annual Report
The report highlights Laboratorios Farmacéuticos ROVI's financial and non-financial performance for the fiscal year 2014, marking its first integrated report. The company achieved record results with a net profit of 24.1 million euros and total revenues of 240.9 million euros, representing a 10% increase from the previous year. ROVI expanded its workforce by 13% to 1,109 employees and invested 12.0 million euros in research and development, particularly focusing on its Risperidone ISM project. Environmentally, the company reduced its water consumption by 8% and electricity consumption by 1% at the group level, while investing 1.9 million euros in health and safety preventive actions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Employees